<DOC>
	<DOCNO>NCT02065076</DOCNO>
	<brief_summary>The purpose trial determine sodium polystyrene sulfonate ( SPS ) effective treatment mild hyperkalemia chronic kidney disease patient follow pre-dialysis nephrology outpatient clinic . Subjects randomize one two treatment arm : 30 g placebo SPS take orally daily seven day . The change serum potassium level compare treatment group . The proportion subject attain normokalemia ( 3.5 5.0 mmol/L ) seven day treatment also compare . Finally , side effect report treatment arm .</brief_summary>
	<brief_title>Efficacy Sodium Polystyrene Sulfonate Treatment Hyperkaliemia Pre-dialysis Patients</brief_title>
	<detailed_description>Background Hyperkalemia affect 10 % patient suffer chronic kidney failure 42 % patient estimate glomerular filtration rate lower 20 mL/min/1.73m2 . There currently limit evidence use sodium polystyrene sulfonate treatment mild hyperkalemia . There even few trial support use several day . To knowledge , one study evaluate chronic use fourteen patient , n't control recent change medication . Since use associate adverse event considerably affect patient ' quality life , appear primordial good assess place treatment hyperkalemia pre-dialysis patient . Methods The aim trial evaluate use sodium polystyrene sulfonate treatment mild asymptomatic hyperkalemia predialysis patient . Participants randomize receive either 30 g placebo 30 g SPS orally daily seven day . Serum potassium level assess baseline day follow last dose treatment . The change serum potassium level proportion patient attain normokalemia compare study group . The incidence adverse event ( nausea , diarrhea , constipation , electrolyte disorder ) also report . Participants also ask fill food diary 3 7 study day . This diary used estimate participant 's average daily intake potassium therefore evaluate similarity diet intervention arm .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperkalemia</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>Aged 18 year Outpatients follow predialysis nephrology clinic MaisonneuveRosemont Hospital Subjects take SPS past 7 day : serum potassium level measure regular followup 4.5 5.5 mmol/L , inclusive , serum potassium level 5.0 5.9 mmol/L , inclusive , one week washout period Subjects take SPS past 7 day : serum potassium level measure regular followup day randomisation 5.0 5.9 , inclusive Subjects contraindication SPS : know hypersensitivity product , history obstructive bowel disease , patient high risk obstructive bowel disease Subjects unable give informed consent Subjects severe symptomatic hyperkalemia require treatment Subjects dialysis ( hemodialysis peritoneal dialysis ) Women pregnant breastfeeding Subjects change dosage insulin past week , change represent 10 % daily total dose 5 unit Subjects stop , start change dosage angiotensin convert enzyme inhibitor , angiotensin II receptor blocker aliskiren past 60 day Subjects stop , start change dosage another medication affect serum potassium level past 30 day Subjects episode decompensated heart failure past 30 day Subjects currently enrol another research protocol Subjects lactose intolerant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Sodium Polystyrene Sulfonate</keyword>
	<keyword>Kayexalate</keyword>
	<keyword>Pre-dialysis</keyword>
	<keyword>Outpatients</keyword>
	<keyword>Hyperkalemia</keyword>
	<keyword>Chronic kidney failure</keyword>
	<keyword>Potassium</keyword>
</DOC>